MingSight Pharmaceuticals is a clinical stage company focused on the development of a new generation, selective inhibitor of protein kinase C (PKC) beta, MS-553.
Major improvements in selectivity, safety and PK enable MS-553 to address the significant shortcomings seen with previous pan-PKC inhibitors.
We have obtained promising proof-of-activity data from ongoing clinical studies in patients with chronic lymphocytic leukemia (CLL) and diabetic macular edema (DME). Here is a link to data from our CLL trial presented at the 2020 Annual Meeting of the America Society of Hematology: https://ash.confex.com/ash/2020/webprogram/Paper142967.html
A Phase 1/2 Study Of The Selective PKC-ß Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
Dr. Zhang has been the CEO of MingSight Pharmaceuticals since its founding. Prior to MingSight, he had more than 10 years of experience in strategic planning and business development in the pharmaceutical industry. These included positions of increasing responsibility at Boehringer Ingelheim and ORA Clinical. He obtained his medical degree from Xiangya School of Medicine in China and his MBA from the Ross Business School of the University of Michigan.
Dr. Niesman is a PhD cell biologist. He spent 10 years in academia, specializing in ocular pharmacology, drug delivery and retinal cell biology before he moved to industry. While at Pfizer, he held multiple roles including global head of ophthalmology research and was a member of the Therapeutic Area Leadership Team in Ophthalmology. He co-founded MingSight with Dr. Zhang.
To contact us, please send a message to: email@example.com
Our mailing address is:
PO Box 261208
San Diego, CA 92196-1208